Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
Views & Analysis 2016 saw slump in FDA drug approvals, but 2017 could be retu... FDA approvals could rebound in 2017 - but concerns about big pharma R&D productivity won't go away.
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
Articles 10 drugs – and their prices – which changed pharma in 2015 In a record-breaking year for pharma, which drugs were the most outstanding?
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
